Eukaryotic initiation factor 5A2 and human digestive system neoplasms.

Meng, Qing-Bin; Peng, Jing-Jing; Qu, Zi-Wei; Zhu, Xiao-Min; Wen, Zhang; Kang, Wei-Ming

Meng, Qing-Bin; Peng, Jing-Jing; Qu, Zi-Wei; Zhu, Xiao-Min; Wen, Zhang; Kang, Wei-Ming.

Afiliação

Meng QB; Department of Gastrointestinal Surgery, the First Hospital of Wuhan City, Wuhan 430022, Hubei Province, China.
Peng JJ; Department of Gastroenterology, General Hospital of the Yangtze River Shipping, Wuhan 430015, Hubei Province, China.
Qu ZW; Department of Gastrointestinal Surgery, the First Hospital of Wuhan City, Wuhan 430022, Hubei Province, China.
Wen Z; Department of Hepato-Biliary-Pancreatic Surgery and Liver Transplantation, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Kang WM; Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. kangweiming@163.com.

World J Gastrointest Oncol ; 11(6): 449-458, 2019 Jun 15.

Article em En | MEDLINE | ID: mdl-31236196

Palavras-chave

Acetylation modification; Cancer therapeutics; Drug resistance; Eukaryotic translation initiation factor 5A2; Hypusine modification

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: World J Gastrointest Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google